<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02124590</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00053117</org_study_id>
    <nct_id>NCT02124590</nct_id>
  </id_info>
  <brief_title>The Effect of Oral Carnitine Supplementation on MRS-derived Mitochondrial Function</brief_title>
  <official_title>The Effect of Oral Carnitine Supplementation on MRS-derived Mitochondrial Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a longitudinal study supported by Pfizer and is a collaboration between DMPI (Duke&#xD;
      Molecular Physiology Institute) and DIAL (Duke Image Acquisition Laboratory) to measure the&#xD;
      effects of acute exercise on carnitine and acylcarnitine levels in the muscle and on insulin&#xD;
      sensitivity in the plasma. This pilot study seeks to explain why moderate intensity exercise&#xD;
      provides more improvements in glucose control for pre-diabetic patients than vigorous&#xD;
      intensity. The investigators hypothesize that moderate intensity exercise might be beneficial&#xD;
      for elderly individuals who are overweight or obese, specifically by: 1. Reducing damaging&#xD;
      excess protein acetylation (measured in muscle biopsy), 2. Improving the&#xD;
      acylcarnitine/carnitine ratio (measured by MRS), 3. Improving overall mitochondrial function&#xD;
      as reflected in reduced phosphocreatine recovery time (measured by MRS) and 4. Increasing&#xD;
      insulin sensitivity as measured by a 4-hour oral glucose tolerance test. Investigators intend&#xD;
      to use the results of this study to show feasibility in measuring mitochondrial function at&#xD;
      Duke for a larger federal grant submission. Investigators hypothesize that carnitine&#xD;
      insufficiency might contribute to mitochondrial dysfunction and obesity-related impairments&#xD;
      in glucose tolerance and insulin action.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Acylcarnitine/Carnitine ratio</measure>
    <time_frame>Baseline, One Month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Protein acetylation</measure>
    <time_frame>Baseline, One Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Sensitivity</measure>
    <time_frame>Baseline, One Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mitochondrial Function</measure>
    <time_frame>Baseline, One Month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Elderly</condition>
  <condition>Pre-diabetic</condition>
  <arm_group>
    <arm_group_label>Acute Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeated isometric leg exercises at varying intensities and a second visit with aerobic bike exercise for 30 minutes at 50% peak VO2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acute Exercise</intervention_name>
    <description>Repeated isometric leg exercises at varying intensities for up to twelve minutes per bout. Leg exercises will target the quadriceps muscles.</description>
    <arm_group_label>Acute Exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acute Exercise</intervention_name>
    <description>Aerobic exercise session on a bike at 50% of peak VO2 for 30 minutes.</description>
    <arm_group_label>Acute Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 60-80 years&#xD;
&#xD;
          -  Moderately Overweight: BMI - 25.0 - 35.4&#xD;
&#xD;
          -  Sedentary - exercise â‰¤ 1 day/week&#xD;
&#xD;
          -  Fasting plasma glucose: &gt; 100 - &lt; 126 mg/dL&#xD;
&#xD;
          -  Readings from two separate days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Orthopedic limitations, musculoskeletal disease and/or injury&#xD;
&#xD;
          -  Allergic to xylocaine&#xD;
&#xD;
          -  Inability to give blood continuously through an intravenous catheter&#xD;
&#xD;
          -  Have a confounding medical condition that is progressive and unstable such as HIV,&#xD;
             Hepatitis C, active cancer, and/or taking medications for those conditions that are&#xD;
             likely to confound the assessment of pre-diabetes&#xD;
&#xD;
          -  Prior surgical operation within the past 6 months&#xD;
&#xD;
          -  Prior injury to the eye involving metallic objects or fragments&#xD;
&#xD;
          -  Prior injury involving a metallic object or foreign body (eg. BB, bullet, shrapnel,&#xD;
             etc.)&#xD;
&#xD;
          -  Tattoos from the waist down to the feet&#xD;
&#xD;
          -  Any of the following implants or devices&#xD;
&#xD;
               -  Aneurysm clip&#xD;
&#xD;
               -  Cardiac pacemaker&#xD;
&#xD;
               -  Implanted cardioverter defibrillator (ICD)&#xD;
&#xD;
               -  Electronic implant or device&#xD;
&#xD;
               -  Magnetically activated implant or device&#xD;
&#xD;
               -  Neurostimulation system&#xD;
&#xD;
               -  Spinal cord stimulator&#xD;
&#xD;
               -  Internal electrodes or wires&#xD;
&#xD;
               -  Bone growth/bone fusion stimulator&#xD;
&#xD;
               -  Cochlear, otologic or other ear implant&#xD;
&#xD;
               -  Insulin or other infusion pump&#xD;
&#xD;
               -  Implanted drug infusion device&#xD;
&#xD;
               -  Eye implants&#xD;
&#xD;
               -  Vascular access port and/or catheter&#xD;
&#xD;
               -  Wire mesh implant or stent&#xD;
&#xD;
               -  Other implant&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Prior knee replacement surgery&#xD;
&#xD;
          -  Pregnant or intending to become pregnant during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William E Kraus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Center for Living</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2014</study_first_posted>
  <last_update_submitted>June 15, 2015</last_update_submitted>
  <last_update_submitted_qc>June 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carnitine</keyword>
  <keyword>Acylcarnitine</keyword>
  <keyword>Exercise</keyword>
  <keyword>Exercise Intensity</keyword>
  <keyword>Insulin Sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

